Recent Developments In ADC Technology: Preclinical Studies Signal Future Clinical Trends

The antibody-drug conjugate (ADC) field is in a transitional period.  Here, experts from Catalent discuss how pre-clinical work is driving rapid evaluation of how we strategize to improve efficacy and reduce toxicity towards better therapeutic outcomes. 

Click here to download article.